The Risk of Acute Myocardial Infarction with Etodolac Is not Increased Compared to Naproxen: A Historical Cohort Analysis of a Generic COX-2 Selective Inhibitor
Free accessResearch articleFirst published online December, 2008
The Risk of Acute Myocardial Infarction with Etodolac Is not Increased Compared to Naproxen: A Historical Cohort Analysis of a Generic COX-2 Selective Inhibitor
Background: This study compares the risk of acute myocardial infarction among patients exposed to etodolac, naproxen, celecoxib, and rofecoxib.
Methods: A retrospective cohort study in 38 258 veteran patients (26 376 patient-years) measured the adjusted odds ratios of acute myocardial infarction during exposure to etodolac, naproxen, celecoxib, or rofecoxib.
Results: Diagnosis of acute myocardial infarction was confirmed in 100 patients who were exposed to a study nonsteroidal anti-inflammatory drug. Compared to naproxen, the increased risk of acute myocardial infarction was not significant for etodolac (OR = 1.32, P = .27), whereas celecoxib (OR = 2.18, 95% CI 1.09-4.35, P = .03) and rofecoxib (OR = 2.16, 95 CI 1.04-4.46, P = .04) were significant. A post hoc analysis indicates that patients with a prior history of acute myocardial infarction had a significant, 4.26-fold risk for another acute myocardial infarction if taking celecoxib or rofecoxib.
Conclusion: Etodolac is not associated with a statistically increased risk of acute myocardial infarction compared to naproxen.
Antman EM, Bennett JS, Daugherty A., Furberg C., Roberts H., Taubert KAUse of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation . 2007;115:1634-1642.
2.
American College of Rheumatology.ACR HOTLINE: The Safety of COX-2 Inhibitors: Delibertions from the February 16-18, 2005, FDA Meeting. http://www.rheumatology.org/publications/hotline/0305COX2.pdf . Accessed August 20, 2008.
3.
Bombardier C. , Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med.2000;343:1520-1528.
4.
Solomon DH, Glynn RJ, Levin R., Avorn J.Nonsteroidal anti-inflammatory drug use and acute myocardial infarction . Arch Intern Med. 2002;162:1099-1104.
5.
Kimmel SE, Berlin JA, Reilly M., et al. The effects of non-selective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol. 2004;43:985-90.
6.
Rahme E., Pilote L., LeLorier J.Association between naproxen use and protection against acute myocardial infarction . Arch Intern Med. 2002;162:1111-1115.
7.
Juni P., Nartey L., Reichenbach S., Sterchi R., Dieppe PA, Egger M.Risk of cardiovascular events and rofecoxib: cumulative meta-analysis . Lancet. 2004;364:2021-2029.
8.
Mamdani M., Rochon P., Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med. 2003;163:481-486.
9.
Ray WA, Stein CM, Hall K., Daugherty JR, Griffin MRNon-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet. 2002 ;359:118-123.
10.
Graham DJ, Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective anti-inflammatory drugs: nested case-control study. Lancet. 2005;365:475-481.
11.
Kearney PM, Baigent C., Godwin J., Halls H., Emberson JR, Patrono C.Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials . BMJ. 2006;332:1302-1308.
12.
McGettigan P., Henry D.Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase. JAMA. 2006; 296:1633-1644.
13.
Farkouh ME, Kirshner H., Harrington RAComparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet. 2004;364:675-684.
14.
Bresalier RS , Sandler RS, Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial . N Engl J Med. 2005;352:1092-1102.
15.
Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-1080.
16.
Warner TD, Giuliano F., Vojnovic I., Bukasa A., Mitchell JA, Vane JRNonsteriod drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis . Proc Natl Acad Sci U S A. 1999;96:7563-7568.
17.
Neustadt DHDouble blind evaluation of the longterm effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. J Rheumatol. 1997;(suppl 47)24: 17-22.
18.
Weideman RA, Kelly KC, Kazi S., et al. Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis. Gastroenterology. 2004;127:1322-1328.
19.
Laine L., Sloane R., Ferretti M., Cominelli F.A randomized, double-blind comparison of placebo, etodolac, and naproxen on grastrointestinal injury and prostaglandin production. Gastrointest Endosc. 1995; 42:428-433.
20.
Motsko SP, Rascati KL, Busti AJ, et al. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf. 2006;29:621-632.
21.
Ray WA, Stein CM, Daugherty JR, Hall K., Arbogast PG, Griffin MRCOX-2 selective non-steroidalantiinflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360:1071-1073.
22.
Solomon SD, Wittes J., Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008;117:2104-2113.
23.
FitzGerald GA, Patrono C.The coxibs, selective inhibitors of cyclooxygenase-2 . N Engl J Med. 2001;345:433-442.
24.
Haffner SM, Lehto SE, Rönnemaa T., Pyörälä K., Laakso M.Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
